Public Health

Crinecerfont, a first-in-class therapy, improved androgen control and reduced reliance on high-dose glucocorticoids for patients with congenital adrenal hyperplasia.

The FDA has approved tirzepatide, the first-ever drug option to treat moderate to severe obstructive sleep apnea in adults with obesity.

Two randomized, double-blind studies demonstrated that a new antipsychotic treatment for adult patients with schizophrenia may lead to a meaningful reduction in symptoms.

The nasal spray is the first vaccine for the prevention of influenza that does not need to be administered by a health care provider.

The first nalmefene hydrochloride auto-injector is another emergency treatment tool to reverse known or suspected opioid overdose.

The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.

The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.

The first orally disintegrating birth control tablet was designed for individuals who have trouble swallowing their medication.

The FDA approved givinostat, a nonsteroidal oral medication, for treating patients 6 years of age or older with Duchenne muscular dystrophy.

The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.